Subject characteristics at baseline
| Treatment group (n=25) | Placebo group (n=25) | p Value | |
| Age in years, mean (SD) | 1.75 (0.9, 4.6) | 2.8 (0.95, 5.25) | 0.34 |
| Men, n (%) | 14 (56) | 12 (48) | 0.58 |
| Cough duration in weeks, median (IQR) | 15.0 (8.5–59) | 11.0 (4.0–28) | 0.18 |
| Smoke exposure, n (%) | 8 (32) | 7 (28) | 0.75 |
| VCD score, median (IQR) | 3.0 (2.0–3.0) | 2.5 (2.0–3.0) | 0.55 |
| CXR abnormal, n (%) | 9 (41%) (n=22) | 6 (30%) (n=20) | 0.56 |
| BAL data | n=19 | n=18 | |
| Total cell count (×109/litre), median (IQR) | 426.0 (196.0–632.0) | 261.0 (185.5–467.5) | 0.45 |
| % Neutrophil, median (IQR) | 38.5 (13.0–58.0) | 34.5 (8.0–66.0) | 0.81 |
| Significant bacterial culture, n (%) | 13 (68) | 14 (78) | 0.78 |
BAL, bronchoalveolar lavage; CXR, chest x-ray; VCD, verbal descriptive category score.17